Comparing BioSig Technologies (BSGM) & BioLife Solutions (BLFS)

BioSig Technologies (NASDAQ:BSGM) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioSig Technologies and BioLife Solutions, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSig Technologies 0 0 2 0 3.00
BioLife Solutions 0 0 4 0 3.00

BioSig Technologies presently has a consensus price target of $12.50, indicating a potential upside of 81.95%. BioLife Solutions has a consensus price target of $17.25, indicating a potential downside of 1.60%. Given BioSig Technologies’ higher probable upside, research analysts clearly believe BioSig Technologies is more favorable than BioLife Solutions.

Volatility & Risk

BioSig Technologies has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioSig Technologies and BioLife Solutions’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSig Technologies N/A N/A -$17.25 million N/A N/A
BioLife Solutions $19.74 million 16.69 $3.27 million $0.14 125.21

BioLife Solutions has higher revenue and earnings than BioSig Technologies.

Profitability

This table compares BioSig Technologies and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSig Technologies N/A -354.26% -284.49%
BioLife Solutions 17.01% 10.32% 9.64%

Insider and Institutional Ownership

4.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 44.0% of BioLife Solutions shares are held by institutional investors. 26.7% of BioSig Technologies shares are held by company insiders. Comparatively, 38.5% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BioLife Solutions beats BioSig Technologies on 9 of the 10 factors compared between the two stocks.

About BioSig Technologies

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.